Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges

FRI0085 Prediciting rheumatoid arthritis by autoantibody testing (PRERA): Preliminary results of a community-based investigation

(2014) M.E. Jimenez Boj et al.   ANNALS OF THE RHEUMATIC DISEASES

OP0041 Tocilizumab (TCZ) in Combination and Monotherapy Versus Methotrexate (MTX) in MTX-Naive Patients (PTS) with Early Rheumatoid Arthritis (RA): Clinical and Radiographic Outcomes from a Randomised, Placebo-Controlled Trial

(2014) G. Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

FRI0164 Predictors of loss of clinical remission with etanercept 50 mg, 25 mg or placebo combined with methotrexate in moderate rheumatoid arthritis patients: Results of the preserve trial:

(2014) J.S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

(2014) Cécile Gaujoux-Viala et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

(2014) Christopher Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy

(2014) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial

(2014) P H de Jong et al.   ANNALS OF THE RHEUMATIC DISEASES

Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis

(2014) Paul Emery et al.   NEW ENGLAND JOURNAL OF MEDICINE

Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs

(2014) Helga Radner et al.   ARTHRITIS RESEARCH & THERAPY

A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors

(2014) Mark C. Genovese et al.   Arthritis & Rheumatology

A178: Development of Tools to Facilitate Shared Decision Making about Medications for Juvenile Idiopathic Arthritis-A Project of the Pediatric Rheumatology Care and Outcomes Improvement Network

(2014) Esi Morgan DeWitt et al.   Arthritis & Rheumatology

What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review

(2013) J A B van Nies et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

(2013) Iain B McInnes et al.   ANNALS OF THE RHEUMATIC DISEASES

How low to aim in rheumatoid arthritis? Learning from other disciplines

(2013) Duncan Porter et al.   ANNALS OF THE RHEUMATIC DISEASES

Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study)

(2013) Jill van Aken et al.   ANNALS OF THE RHEUMATIC DISEASES

Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials

(2013) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Proposal for a new nomenclature of disease-modifying antirheumatic drugs: Table 1

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)

(2013) J L Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis

(2013) Maurizio Cutolo et al.   AUTOIMMUNITY REVIEWS

Treat-to-target trials: uses, interpretation and review of concepts

(2013) A. J. Garber   DIABETES OBESITY & METABOLISM

Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study

(2013) W. Stohl et al.   JOURNAL OF RHEUMATOLOGY

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

(2013) Iain B McInnes et al.   LANCET

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

(2013) Dominique Baeten et al.   LANCET

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

(2013) Josef S Smolen et al.   LANCET

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

(2013) Josef S Smolen et al.   LANCET

B-cell targeted therapeutics in clinical development

(2013) Stephan Blüml et al.   ARTHRITIS RESEARCH & THERAPY

Review: Treat to Target in Rheumatoid Arthritis: Fact, Fiction, or Hypothesis?

(2013) Daniel H. Solomon et al.   Arthritis & Rheumatology

In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis

(2012) Garifallia Sakellariou et al.   ANNALS OF THE RHEUMATIC DISEASES

Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis

(2012) Katja Thiele et al.   ANNALS OF THE RHEUMATIC DISEASES

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

(2012) Jacqueline Detert et al.   ANNALS OF THE RHEUMATIC DISEASES

Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study

(2012) Marije F Bakker et al.   ANNALS OF THE RHEUMATIC DISEASES

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial

(2012) P H de Jong et al.   ANNALS OF THE RHEUMATIC DISEASES

Forget personalised medicine and focus on abating disease activity

(2012) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

(2012) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials

(2012) Karim Raza et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study

(2012) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis

(2012) Danielle M Gerlag et al.   ANNALS OF THE RHEUMATIC DISEASES

Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis

(2012) M. Bonelli et al.   ARTHRITIS AND RHEUMATISM

Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis

(2012) Nikolaus B. Binder et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

(2012) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study

(2012) M. E. Weinblatt et al.   RHEUMATOLOGY

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

(2012) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort

(2012) Marloes Vermeer et al.   ARTHRITIS RESEARCH & THERAPY

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

(2011) M. H. Buch et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating rheumatoid arthritis to target: the patient version of the international recommendations

(2011) M. P. T. de Wit et al.   ANNALS OF THE RHEUMATIC DISEASES

Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study

(2011) S. A. Provan et al.   ANNALS OF THE RHEUMATIC DISEASES

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

(2011) D. T. Felson et al.   ANNALS OF THE RHEUMATIC DISEASES

Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints

(2011) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search

(2010) M. Schoels et al.   ANNALS OF THE RHEUMATIC DISEASES

The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis

(2010) K. P. Machold et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating rheumatoid arthritis to target: recommendations of an international task force

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?

(2010) B. Saleem et al.   ANNALS OF THE RHEUMATIC DISEASES

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study

(2010) Y. Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

(2010) P. P. Tak et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants

(2010) Josef S. Smolen et al.   ARTHRITIS AND RHEUMATISM

Does Clinical Remission Lead to Normalization of EQ-5D in Patients with Rheumatoid Arthritis and Is Selection of Remission Criteria Important?

(2010) L. LINDE et al.   JOURNAL OF RHEUMATOLOGY

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard

(2010) A. Balsa et al.   RHEUMATOLOGY

Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis

(2009) R. O'Mahony et al.   ANNALS OF THE RHEUMATIC DISEASES

Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials

(2009) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

(2009) R Westhovens et al.   ANNALS OF THE RHEUMATIC DISEASES

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

(2009) Stanley B. Cohen et al.   ARTHRITIS AND RHEUMATISM

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

(2009) Paul Emery et al.   ARTHRITIS AND RHEUMATISM

Effect of discontinuing TNFα antagonist therapy in patients with remission of rheumatoid arthritis

(2009) Olivier Brocq et al.   JOINT BONE SPINE

The Michael Mason prize: early rheumatoid arthritis--the window narrows

(2009) K. Raza   RHEUMATOLOGY

Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade

(2008) J S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

(2008) J Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature

(2008) K Visser et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab, a human antibody to tumour necrosis factor   given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

(2008) E C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

The importance of reporting disease activity states in rheumatoid arthritis clinical trials

(2008) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

(2008) Edward Keystone et al.   ARTHRITIS AND RHEUMATISM

Cytokines as Therapeutic Targets: Advances and Limitations

(2008) Clemens Scheinecker et al.   IMMUNITY

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

(2008) Paul Emery et al.   LANCET

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

(2007) M Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES